Research

Hormonal

The cardiometabolic benefits of semaglutide 2.4 mg are not maintained after treatment discontinuation, with risk factors deteriorating towards baseline levels.

If you stop taking semaglutide 2.4 mg, the improvements in your blood pressure, blood sugar, and cholesterol will likely reverse towards your pre-treatment levels. This suggests that obesity management with this medication requires long-term, continuous use.

WeakRefutesVERY_HIGH confidence
In STEP 4, improvements in waist circumference, SBP, FPG, fasting serum insulin and lipids during the semaglutide run-in (week 0-20) were maintained over week 20-68 with continued semaglutide, but deteriorated following the switch to placebo (p < .001 [week 20-68]).
Mikhail Kosiborod et al. · Diabetes Obesity and Metabolism · 2022

Why this rating

Based on the randomized withdrawal phase of STEP 4, a robust trial design.

Source

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: <scp>STEP</scp> 1 and 4 exploratory analyses

Mikhail Kosiborod et al. · Diabetes Obesity and Metabolism · 2022

DOI 10.1111/dom.14890

rct · n=2764Cited 107×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →